[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

Stopped early · Phase 2

Conditions studied: Pain

In brief

The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of \[S,S\]-Reboxetine in patients with pain after shingles.

Key facts

Study ID

NCT00354094

Run by

Pfizer

People needed

600

Starts

2006-11-01

Expected to finish

2007-10-01

Last updated by the study team

2007-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have pain present for more than 3 months after healing of the shingles skin rash.
• Patients at screening must have a score of >/=40mm on the pain visual analogue scale.

You may not qualify if…

• Patients with significant hepatic impairment.
• Patients with other severe pain, that may impair the self-assessment of pain due to postherpetic neuralgia (pain after shingles).

Where it is running

• Pfizer Investigational Site — Tampa, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Greensboro, North Carolina, United States
• Pfizer Investigational Site — Fargo, North Dakota, United States
• Pfizer Investigational Site — Cumberland, Rhode Island, United States
• Pfizer Investigational Site — San Antonio, Texas, United States
• Pfizer Investigational Site — Buenos Aires, Buenos Aires, Argentina
• Pfizer Investigational Site — Buenos Aires, Argentina
• Pfizer Investigational Site — Buenos Aires, Argentina
• Pfizer Investigational Site — Buenos Aires, Argentina
• Pfizer Investigational Site — Greater Sudbury, Ontario, Canada
• Pfizer Investigational Site — Greater Sudbury, Ontario, Canada
• Pfizer Investigational Site — Greater Sudbury, Ontario, Canada
• Pfizer Investigational Site — Toronto, Ontario, Canada
• Pfizer Investigational Site — Montreal, Quebec, Canada
• Pfizer Investigational Site — Santiago, RM, Chile
• Pfizer Investigational Site — Viña del Mar, Valparaiso, Chile
• Pfizer Investigational Site — Split, Croatia
• Pfizer Investigational Site — Hyderabad, Andhra Pradhesh, India
• Pfizer Investigational Site — Chandigarh, Punjab, India
• Pfizer Investigational Site — Bangalore, India
• Pfizer Investigational Site — Chennai, India
• Pfizer Investigational Site — Hyderabad, India
• Pfizer Investigational Site — New Delhi, India
• Pfizer Investigational Site — New Delhi, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.